Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Aberrant B-Raf Signaling in Human Cancer − 10 Years from Bench to Bedside

Volumen 17, Edición 1, 2012, pp. 97-121
DOI: 10.1615/CritRevOncog.v17.i1.70
Get accessGet access

SINOPSIS

The Ras/Raf/MEK/ERK signaling pathway plays a key role in physiological processes and is often dysregulated in cancer as well as developmental disorders such as the neuro-cardio-facio-cutaneous syndromes. Raf proteins, and in particular B-Raf, represent an important regulatory node, which is reflected by the fact that B-Raf represents the most frequently mutated protein kinase gene in human tumors. Many genetic aberrations of the BRAF proto-oncogene, such as different point mutations and chromosomal rearrangements, have been reported since 2002. As B-Raf displays aberrant activity in tumor entities for which no or only limited effective therapies are available, e.g., melanoma, ovarian, and colorectal carcinoma, a lot of hope and effort has been placed on strategies inhibiting its activity. Indeed, recent clinical trials involving B-Raf selective inhibitors exhibited unprecedented response rates in metastatic melanoma patients. However, this therapeutic response is short-lived due to the emergence of several resistance mechanisms. Here we provide a review of our current knowledge on the regulation of this kinase under physiological circumstances and how this control is lost by mutations. We give an update on malignancies displaying high frequencies of BRAF mutations and discuss the mechanisms underlying the side effects and drug resistance phenomena associated with Raf inhibitors.

CITADO POR
  1. Pakladok Tatsiana, Hosseinzadeh Zohreh, Alesutan Ioana, Lang Florian, Stimulation of the Na+-coupled glucose transporter SGLT1 by B-RAF, Biochemical and Biophysical Research Communications, 427, 4, 2012. Crossref

  2. Aravalli Rajagopal N., Cressman Erik N. K., Steer Clifford J., Cellular and molecular mechanisms of hepatocellular carcinoma: an update, Archives of Toxicology, 87, 2, 2013. Crossref

  3. González Mercedes, Cerecetto Hugo, Quinoxaline derivatives: a patent review (2006 – present), Expert Opinion on Therapeutic Patents, 22, 11, 2012. Crossref

  4. Machesky Laura M., Sansom Owen J., Rac1 in the driver’s seat for melanoma, Pigment Cell & Melanoma Research, 25, 6, 2012. Crossref

  5. Freeman Alyson K, Ritt Daniel A, Morrison Deborah K, The importance of Raf dimerization in cell signaling, Small GTPases, 4, 3, 2013. Crossref

  6. Yaktapour Niuscha, Übelhart Rudolf, Schüler Julia, Aumann Konrad, Dierks Christine, Burger Meike, Pfeifer Dietmar, Jumaa Hassan, Veelken Hendrik, Brummer Tilman, Zirlik Katja, Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia, Blood, 122, 9, 2013. Crossref

  7. Baljuls Angela, Kholodenko Boris N., Kolch Walter, It takes two to tango – signalling by dimeric Raf kinases, Mol. BioSyst., 9, 4, 2013. Crossref

  8. Field Jeffrey, Manser Ed, The PAKs come of age, Cellular Logistics, 2, 2, 2012. Crossref

  9. Uhara Hisashi, Ashida Atsuko, Koga Hiroshi, Ogawa Eisaku, Uchiyama Aya, Uchiyama Ryuhei, Hayashi Koichi, Kiniwa Yukiko, Okuyama Ryuhei, NRAS mutations in primary and metastatic melanomas of Japanese patients, International Journal of Clinical Oncology, 19, 3, 2014. Crossref

  10. Xie Tian, Peng Wei, Liu Yexing, Yan Chuangye, Maki Jenny, Degterev Alexei, Yuan Junying, Shi Yigong, Structural Basis of RIP1 Inhibition by Necrostatins, Structure, 21, 3, 2013. Crossref

  11. Khazak Vladimir, Eyrisch Susanne, Kato Juran, Tamanoi Fuyuhiko, Golemis Erica A., A Two-Hybrid Approach to Identify Inhibitors of the RAS–RAF Interaction, in Inhibitors of the Ras Superfamily G-proteins, Part A, 33, 2013. Crossref

  12. Pakladok Tatsiana, Hosseinzadeh Zohreh, Lebedeva Aleksandra, Alesutan Ioana, Lang Florian, Upregulation of the Na+-Coupled Phosphate Cotransporters NaPi-IIa and NaPi-IIb by B-RAF, The Journal of Membrane Biology, 247, 2, 2014. Crossref

  13. Ascierto Paolo A, Schadendorf Dirk, Berking Carola, Agarwala Sanjiv S, van Herpen Carla ML, Queirolo Paola, Blank Christian U, Hauschild Axel, Beck J Thaddeus, St-Pierre Annie, Niazi Faiz, Wandel Simon, Peters Malte, Zubel Angela, Dummer Reinhard, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, The Lancet Oncology, 14, 3, 2013. Crossref

  14. McKelvie Penelope A., Chan Fiona, Yu Yong, Waring Paul, Gresshoff Irma, Farrell Stephen, Williams Richard A., The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry, Pathology, 45, 7, 2013. Crossref

  15. Fuchs Serge Y., Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy, Journal of Interferon & Cytokine Research, 33, 4, 2013. Crossref

  16. Hemminger J.A., Lozanski G., Molecular Pathology of Chronic Lymphocytic Leukemia and Relevance to Novel Therapies, in Pathobiology of Human Disease, 2014. Crossref

  17. Coupe Nicholas, Corrie Pippa, Hategan Mirela, Larkin James, Gore Martin, Gupta Avinash, Wise Adelyn, Suter Sam, Ciria Cristian, Love Sharon, Collins Linda, Middleton Mark R., PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel, European Journal of Cancer, 51, 3, 2015. Crossref

  18. Yaktapour Niuscha, Meiss Frank, Mastroianni Justin, Zenz Thorsten, Andrlova Hana, Mathew Nimitha R., Claus Rainer, Hutter Barbara, Fröhling Stefan, Brors Benedikt, Pfeifer Dietmar, Pantic Milena, Bartsch Ingrid, Spehl Timo S., Meyer Philipp T., Duyster Justus, Zirlik Katja, Brummer Tilman, Zeiser Robert, BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia, Journal of Clinical Investigation, 124, 11, 2014. Crossref

  19. Dudley Jonathan C., Gurda Grzegorz T., Tseng Li-Hui, Anderson Derek A., Chen Guoli, Taube Janis M., Gocke Christopher D., Eshleman James R., Lin Ming-Tseh, Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma, Molecular Diagnosis & Therapy, 18, 4, 2014. Crossref

  20. Grimaldi Antonio M., Simeone Ester, Ascierto Paolo A., The role of MEK inhibitors in the treatment of metastatic melanoma, Current Opinion in Oncology, 26, 2, 2014. Crossref

  21. Lloyd K. C. Kent, Khanna Chand, Hendricks William, Trent Jeffrey, Kotlikoff Michael, Precision medicine: an opportunity for a paradigm shift in veterinary medicine, Journal of the American Veterinary Medical Association, 248, 1, 2016. Crossref

  22. Hou Jiayun, Zhang Yong, Zhu Zhitu, Gene heterogeneity in metastasis of colorectal cancer to the lung, Seminars in Cell & Developmental Biology, 64, 2017. Crossref

  23. Egeler R. Maarten, Katewa Satyendra, Leenen Pieter J.M., Beverley Peter, Collin Matthew, Ginhoux Florent, Arceci Robert J., Rollins Barrett J., Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci, Pediatric Blood & Cancer, 63, 10, 2016. Crossref

  24. Pakladok Tatsiana, Hosseinzadeh Zohreh, Almilaji Ahmad, Lebedeva Aleksandra, Shumilina Ekaterina, Alesutan Ioana, Lang Florian, Barnes Steven, Up-Regulation of hERG K+ Channels by B-RAF, PLoS ONE, 9, 1, 2014. Crossref

  25. Brummer Tilman, BRaf-Signaling, in Encyclopedia of Cancer, 2017. Crossref

  26. Brummer Tilman, BRAF Somatic Alterations, in Encyclopedia of Cancer, 2017. Crossref

  27. Grimaldi Antonio M., Simeone Ester, Festino Lucia, Vanella Vito, Strudel Martina, Ascierto Paolo A., MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors, American Journal of Clinical Dermatology, 18, 6, 2017. Crossref

  28. Geng Jiangqiao, Wang Huanmin, Liu Yuanhu, Tai Jun, Jin Yaqiong, Zhang Jie, He Lejian, Fu Libing, Qin Hong, Song Yingluan, Su Jinzhu, Zhang Aiying, Wen Xin, Guo Yongli, Ni Xin, Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma, Science China Life Sciences, 60, 7, 2017. Crossref

  29. WEI RUI, WANG ZHONGQING, LI XIAOLIN, SHU YIGANG, FU BIN, Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis, Biomedical Reports, 1, 3, 2013. Crossref

  30. LI BIN, LU JING CHEN, HE DAN, WANG JUN, ZHOU HUI, SHEN LIANGFANG, ZHANG CHUNFANG, DUAN CHAOJUN, Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report, Oncology Letters, 8, 2, 2014. Crossref

  31. Neal Donald E, Derwae Amanda L, Etzkorn Jeremy R, Cells to Surgery Quiz: March 2018, Journal of Investigative Dermatology, 138, 3, 2018. Crossref

  32. Brummer Tilman, B-Raf Somatic Alterations, in Encyclopedia of Cancer, 2014. Crossref

  33. Brummer Tilman, B-Raf Signaling, in Encyclopedia of Cancer, 2014. Crossref

  34. Köhler Martin, Ehrenfeld Sophia, Halbach Sebastian, Lauinger Manuel, Burk Ulrike, Reischmann Nadine, Cheng Shuofei, Spohr Corinna, Uhl Franziska Maria, Köhler Natalie, Ringwald Kathrin, Braun Sandra, Peters Christoph, Zeiser Robert, Reinheckel Thomas, Brummer Tilman, B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model, Oncogene, 38, 8, 2019. Crossref

  35. Freeman Alyson K., Morrison Deborah K., Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer, in Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy, 1, 2013. Crossref

  36. Aravalli Rajagopal N., Steer Clifford J., Molecular Mechanisms of HCC, in Hepatocellular Carcinoma, 2014. Crossref

  37. Köhler Martin, Röring Michael, Schorch Björn, Heilmann Katharina, Stickel Natalie, Fiala Gina J, Schmitt Lisa C, Braun Sandra, Ehrenfeld Sophia, Uhl Franziska M, Kaltenbacher Thorsten, Weinberg Florian, Herzog Sebastian, Zeiser Robert, Schamel Wolfgang W, Jumaa Hassan, Brummer Tilman, Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants , The EMBO Journal, 35, 2, 2016. Crossref

  38. Diedrich Britta, Rigbolt Kristoffer TG, Röring Michael, Herr Ricarda, Kaeser‐Pebernard Stephanie, Gretzmeier Christine, Murphy Robert F, Brummer Tilman, Dengjel Jörn, Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition , The EMBO Journal, 36, 5, 2017. Crossref

  39. Parsyan Armen, Sullivan Ryan J., Meguerditchian Ari-Nareg, Meterissian Sarkis, Melanoma and Non-Melanoma Skin Cancers, in Translation and Its Regulation in Cancer Biology and Medicine, 2014. Crossref

  40. Morkel Markus, Riemer Pamela, Bläker Hendrik, Sers Christine, Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance, Oncotarget, 6, 25, 2015. Crossref

  41. Eisenhardt Anja E., Sprenger Adrian, Röring Michael, Herr Ricarda, Weinberg Florian, Köhler Martin, Braun Sandra, Orth Joachim, Diedrich Britta, Lanner Ulrike, Tscherwinski Natalja, Schuster Simon, Dumaz Nicolas, Schmidt Enrico, Baumeister Ralf, Schlosser Andreas, Dengjel Jörn, Brummer Tilman, Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles, Oncotarget, 7, 18, 2016. Crossref

  42. Behar Marcelo, Barken Derren, Werner Shannon L., Hoffmann Alexander, The Dynamics of Signaling as a Pharmacological Target, Cell, 155, 2, 2013. Crossref

  43. Catalano Antonella, Adlesic Mojca, Kaltenbacher Thorsten, Klar Rhena F. U., Albers Joachim, Seidel Philipp, Brandt Laura P., Hejhal Tomas, Busenhart Philipp, Röhner Niklas, Zodel Kyra, Fritsch Kornelia, Wild Peter J., Duyster Justus, Fritsch Ralph, Brummer Tilman, Frew Ian J., Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition, Cancers, 13, 8, 2021. Crossref

  44. Schenone Silvia, Radi Marco, Musumeci Francesca, Brullo Chiara, Botta Maurizio, Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies, Chemical Reviews, 114, 14, 2014. Crossref

  45. Freeman Alyson K., Ritt Daniel A., Morrison Deborah K., Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling, Molecular Cell, 49, 4, 2013. Crossref

  46. Rezaei Adariani Soheila, Buchholzer Marcel, Akbarzadeh Mohammad, Nakhaei-Rad Saeideh, Dvorsky Radovan, Ahmadian Mohammad Reza, Structural snapshots of RAF kinase interactions, Biochemical Society Transactions, 46, 6, 2018. Crossref

  47. Harlid Sophia, Van Guelpen Bethany, Qu Conghui, Gylling Björn, Aglago Elom K., Amitay Efrat L., Brenner Hermann, Buchanan Daniel D., Campbell Peter T., Cao Yin, Chan Andrew T., Chang‐Claude Jenny, Drew David A., Figueiredo Jane C., French Amy J., Gallinger Steven, Giannakis Marios, Giles Graham G., Gunter Marc J., Hoffmeister Michael, Hsu Li, Jenkins Mark A., Lin Yi, Moreno Victor, Murphy Neil, Newcomb Polly A., Newton Christina C., Nowak Jonathan A., Obón‐Santacana Mireia, Ogino Shuji, Potter John D., Song Mingyang, Steinfelder Robert S., Sun Wei, Thibodeau Stephen N., Toland Amanda E., Ugai Tomotaka, Um Caroline Y., Woods Michael O., Phipps Amanda I., Harrison Tabitha, Peters Ulrike, Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases, International Journal of Cancer, 151, 3, 2022. Crossref

  48. McCarthy Jeanette J., McLeod Howard L., Ginsburg Geoffrey S., Genomic Medicine: A Decade of Successes, Challenges, and Opportunities, Science Translational Medicine, 5, 189, 2013. Crossref

  49. Favre Gilles, Le devenir des thérapeutiques ciblant la voie RAS/RAF/ MEK/ERK en cancérologie : l’exemple des mélanomes, Bulletin de l'Académie Nationale de Médecine, 198, 2, 2014. Crossref

  50. Mitra Shahana, Ghosh Baijayanti, Gayen Nilanjan, Roy Joydeep, Mandal Atin K., Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation, Journal of Biological Chemistry, 291, 47, 2016. Crossref

  51. Clerk Angela, Meijles Daniel N., Hardyman Michelle A., Fuller Stephen J., Chothani Sonia P., Cull Joshua J., Cooper Susanna T.E., Alharbi Hajed O., Vanezis Konstantinos, Felkin Leanne E., Markou Thomais, Leonard Samuel J., Shaw Spencer W., Rackham Owen J.L., Cook Stuart A., Glennon Peter E., Sheppard Mary N., Sembrat John C., Rojas Mauricio, McTiernan Charles F., Barton Paul J., Sugden Peter H., Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo , Biochemical Journal, 479, 3, 2022. Crossref

  52. Krejci Pavel, The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while other cells over proliferate, Mutation Research/Reviews in Mutation Research, 759, 2014. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain